Morphine Sulfate

Riik: Uus-Meremaa

keel: inglise

Allikas: Medsafe (Medicines Safety Authority)

Toimeaine:

Morphine sulfate pentahydrate 15 mg/mL;  

Saadav alates:

Medsurge Pharma Limited

Annus:

15 mg/mL

Ravimvorm:

Solution for injection

Koostis:

Active: Morphine sulfate pentahydrate 15 mg/mL   Excipient: Hydrochloric acid Nitrogen Sodium chloride Water for injection

Retsepti tüüp:

Class B1 Controlled Drug

Näidustused:

The short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Toote kokkuvõte:

Package - Contents - Shelf Life: Ampoule, glass, Type 1 coloured, 1mL - 5 dose units - 30 months from date of manufacture stored at or below 25°C protect from light 24 hours opened stored at 2° to 8°C (Refrigerate, do not freeze) 24 hours diluted stored at 2° to 8°C (Refrigerate, do not freeze) - Ampoule, glass, Type 1 coloured, 1mL - 50 dose units - 30 months from date of manufacture stored at or below 25°C protect from light 24 hours opened stored at 2° to 8°C (Refrigerate, do not freeze) 24 hours diluted stored at 2° to 8°C (Refrigerate, do not freeze)

Loa andmise kuupäev:

2019-08-15

Toote omadused

MORPHINE SULFATE
NEW ZEALAND DATA SHEET
New Zealand Data Sheet Edition 4.0
Page 1 of 24
NEW ZEALAND DATA SHEET
WARNINGS
LIMITATIONS OF USE
Because of the risks associated with the use of opioids, morphine
should only be used in patients for
whom other treatment options, including non-opioid analgesics, are
ineffective, not tolerated or
otherwise
inadequate
to
provide
appropriate
management
of
pain
(see
section
4.4
SPECIAL
WARNINGS AND PRECAUTIONS FOR USE).
HAZARDOUS AND HARMFUL USE
Morphine poses risks of hazardous and harmful use which can lead to
overdose and death. Assess the
patient’s risk of hazardous and harmful use before prescribing and
monitor the patient regularly
during treatment (see section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR
USE).
LIFE-THREATENING RESPIRATORY DEPRESSION
Serious, life-threatening or fatal respiratory depression may occur
with the use of morphine. Be
aware of situations which increase the risk of respiratory depression,
modify dosing in patients at risk
and monitor patients closely, especially on initiation or following a
dose increase (see section 4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE).
CONCOMITANT USE OF BENZODIAZEPINES AND OTHER CENTRAL NERVOUS SYSTEM
(CNS) DEPRESSANTS, INCLUDING
ALCOHOL
Concomitant use of opioids with other opioid analgesics,
benzodiazepines, gabapentinoids, cannabis,
sedatives, hypnotics, tricyclic antidepressants, antipsychotics,
antihistamines, centrally-active anti-
emetics, general anaesthetics, tranquilisers, beta blocker, or other
central nervous system (CNS)
depressants, including alcohol, may result in profound sedation,
respiratory depression, coma, and
death. Limit dosages and durations to the minimum required; and
monitor patients for signs and
symptoms of respiratory depression and sedation. Caution patients not
to drink alcohol while using
morphine (see section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE).
1
PRODUCT NAME
MORPHINE SULFATE 2 mg/1 mL (MEDICIANZ) solution for injection
MORPHINE SULFATE 5 mg/1 mL (MEDICIANZ) solution for in